A single or multiple administration of fluconazole at a dose of 50 mg does not affect the metabolism of phenazone (Antipyrin) when they are taken concomitantly.
The simultaneous use of fluconazole with the following drugs is contraindicated:
Cisapride: with the simultaneous use of fluconazole and cisapride, unwanted reactions from the heart are possible, including arrhythmia of the ventricular tachysystolic type "pirouette" (torsade de pointes). The use of fluconazole at a dose of 200 mg 1 time per day and cisapride in a dose of 20 mg 4 times a day leads to a marked increase in plasma concentrations of cisapride and an increase in the interval QT on the ECG. Simultaneous administration of cisapride and fluconazole is contraindicated.
Terfenadine: with the simultaneous use of azole antifungal agents and terfenadine, serious arrhythmias can occur as a result of an increase in the interval QT. When taking fluconazole at a dose of 200 mg / day increasing the interval QT is not established, however, the use of fluconazole at doses of 400 mg / day and higher causes a significant increase in the concentration of terfenadine in the blood plasma. Simultaneous administration of fluconazole in doses of 400 mg / day or more with terfenadine is contraindicated (see.section "Contraindications"). Treatment with fluconazole in doses less than 400 mg / day in combination with terfenadine should be carefully monitored.
Astemizole: the simultaneous use of fluconazole with astemizole or other drugs metabolized by the cytochrome P450 system may be accompanied by an increase in the serum concentrations of these agents. Elevated concentrations of astemizole in the blood plasma can lead to lengthening of the interval QT and in some cases, to the development of ventricular arrhythmia of tachysystolic type "pirouette" (torsade de pointes). Simultaneous use of astemizole and fluconazole is contraindicated.
Pimozide: Despite the fact that no relevant studies have been carried out in vitro or in vivo, simultaneous application of fluconazole and pimozide can lead to inhibition of the metabolism of pimozide. In turn, an increase in the plasma concentrations of pimozide can lead to lengthening of the interval QT and in some cases, the development of ventricular arrhythmia of tachysystolic type "pirouette" (torsade de pointes). Simultaneous use of pimozide and fluconazole is contraindicated.
Quinidine: Despite the fact that no relevant studies have been carried out in vitro or in vivo, simultaneous application of fluconazole and quinidine may also lead to inhibition of quinidine metabolism. The use of quinidine is associated with lengthening the interval QT and in some cases with the development of ventricular arrhythmia of tachysystolic type "pirouette" (torsade de pointes). Simultaneous use of quinidine and fluconazole is contraindicated.
Erythromycin: simultaneous application of fluconazole and erythromycin potentially leads to an increased risk of cardiotoxicity (lengthening of the interval QT, torsade de pointes) and, as a result, sudden cardiac death. The simultaneous use of fluconazole and erythromycin is contraindicated.
Tofacitinib: The exposure to tofacitinib increases with its combined use with drugs that are both moderate inhibitors of the isoenzyme CYP3A4 and potent inhibitors of isoenzyme CYP2C19 (for example fluconazole). It may be necessary to correct the dose of tofacitinib.
Care should be taken and, perhaps, adjust the dose with the simultaneous use of the following drugs and fluconazole:
Drugs affecting fluconazole:
Hydrochlorothiazide: the repeated use of hydrochlorothiazide simultaneously with fluconazole leads to an increase in the concentration of fluconazole in the blood plasma by 40%. The effect of such a degree of expression does not require a change in the dosage regimen of fluconazole in patients receiving both diuretics at the same time, but the doctor should take this into account.
Rifampicin: simultaneous application of fluconazole and rifampicin leads to a decrease AUC by 25% and the duration of the half-life of fluconazole by 20%. In patients who simultaneously take rifampicin, it is necessary to consider the advisability of increasing the dose of fluconazole.
Drugs affected by fluconazole:
Fluconazole is a potent inhibitor of isoenzyme CYP2C9 and CYP2C19 cytochrome P450 and moderate inhibitor of isoenzyme CYP3A4. In addition, in addition to the effects listed below, there is a risk of increasing plasma concentrations of blood and other drugs metabolized by isoenzymes CYP2C9 and CYP2C19 and CYP3A4 with simultaneous admission with fluconazole.
In this regard, caution should be exercised when using these drugs at the same time, and if necessary, such combinations should be carefully monitored by patients.It should be borne in mind that the inhibitory effect of fluconazole persists for 4-5 days after discontinuation of the drug due to a prolonged half-life.
Alfentanil: there is a decrease in clearance and volume of distribution, an increase in the half-life of alfentanil. Perhaps this is due to inhibition of the isoenzyme CYP3A4 with fluconazole. Alfventanyl dosage adjustment may be required.
Amitriptyline, nortriptyline: increase in effect. The concentration of 5-nortryptiline and / or Samitriptyline can be measured at the beginning of a combination therapy with fluconazole and a week after the start of treatment. If necessary, adjust the dose of amitriptyline / nortriptyline.
Amphotericin B: in studies on mice (including immunosuppression), the following results were noted: a slight additive antifungal effect in systemic infection caused by FROM. albicans, lack of interaction with intracranial infection caused by Cryptococcus neoformans, and antagonism with systemic infection caused by A. fumigatus. The clinical significance of these results is not clear.
Anticoagulants: as well as other antifungal agents (azole derivatives), fluconazole, with simultaneous application with warfarin, increases prothrombin time (by 12%), which is why bleeding may develop (hematomas, nosebleeds and gastrointestinal tract, hematuria, melena). In patients receiving coumarin anticoagulants and fluconazole, it is necessary to constantly monitor prothrombin time during therapy and within 8 days after simultaneous use. Also, the appropriateness of correcting the dose of warfarin should be evaluated.
Azithromycin: with the simultaneous administration of fluconazole in a single dose of 800 mg with azithromycin in a single dose of 1200 mg expressed pharmacokinetic interaction between both drugs is not established.
Benzodiazepines (short-acting): after ingestion of midazolam fluconazole significantly increases the concentration of midazolam and psychomotor effects, and this effect is more pronounced after taking fluconazole orally than with its use intravenously. If concomitant therapy with benzodiazepines is required in patients taking fluconazole, should be monitored to assess the appropriateness of an appropriate dose reduction for benzodiazepine.
With the simultaneous administration of a single dose of triazolam fluconazole increases the AUC triazolam by approximately 50%, CmOh - by 25-50% and half-life - by 25-50%, due to inhibition of the metabolism of triazolam. You may need to adjust the dose of triazolam.
Carbamazepine: fluconazole It inhibits the metabolism of carbamazepine and increases the serum concentration of carbamazepine by 30%. It is necessary to consider the risk of development of toxicity of carbamazepine. It is necessary to evaluate the need for correcting the dose of carbamazepine as a function of concentration / effect.
Calcium channel blockers: some calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil and felodipine) are metabolized by isoenzyme CYP3A4. Fluconazole increases the systemic exposure of calcium channel antagonists. It is recommended to control the development of side effects.
Cyclosporin: In patients with a transplanted kidney, the use of fluconazole at a dose of 200 mg / day leads to a slow increase in the concentration of cyclosporine. However, with repeated administration of fluconazole at a dose of 100 mg / day, changes in the concentration of cyclosporin in bone marrow recipients were not observed.With the simultaneous use of fluconazole and cyclosporine, it is recommended to monitor the concentration of cyclosporine in the blood.
Cyclophosphamide: with the simultaneous use of cyclophosphamide and fluconazole, there is an increase in serum concentrations of bilirubin and creatinine. This combination is acceptable given the risk of increasing concentrations of bilirubin and creatinine.
Fentanyl: there is a report of one fatal outcome, possibly associated with simultaneous administration of fentanyl and fluconazole. It is assumed that the violations are associated with intoxication with fentanyl. It was shown that fluconazole significantly prolongs the excretion time of fentanyl. It should be borne in mind that an increase in the concentration of fentanyl may lead to inhibition of respiratory function.
Halofantrine: fluconazole can increase the concentration of halophanthin in the blood plasma in connection with the inhibition of the isoenzyme CYP3A4. With simultaneous use with fluconazole, as with other antifungal azole agents, the possibility of arrhythmia of the ventricular tachysystolic type "pirouette" increases. Their joint use is not recommended.
Inhibitors of HMG-CoA reductase: with simultaneous application of fluconazole with inhibitors of HMG-CoA reductase, metabolized by isoenzyme CYP3A4 (such as atorvastatin and simvastatin) or isoenzyme CYP2D6 (such as fluvastatin), the risk of developing myopathy and rhabdomyolysis increases. In case of need for simultaneous therapy with these drugs, patients should be observed to identify the symptoms of myopathy and rhabdomyolysis. It is necessary to monitor the concentration of creatinine kinase. In the case of a significant increase in the concentration of creatinine kinase or if there is a diagnosis or suspected development of myopathy or rhabdomyolysis, therapy with HMG-CoA reductase inhibitors should be discontinued.
Losartan: fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74), which is responsible for most of the effects associated with angiotensin II receptor antagonism. Regular monitoring of blood pressure is necessary.
Methadone: fluconazole may increase the plasma concentration of methadone. Methadone dose adjustment may be necessary.
Non-steroidal anti-inflammatory drugs (NSAIDs)): FROMmOh and AUC of flurbiprofen are increased by 23% and 81%, respectively. Similarly, CmOh and the AUC of the pharmacologically active isomer [S- (+) - ibuprofen] increased by 15% and 82%, respectively, with simultaneous application of fluconazole with racemic ibuprofen (400 mg).
With the simultaneous use of fluconazole at a dose of 200 mg / sug and celecokeib at a dose of 200 mg CmOh and AUC celecoxib increased by 68% and 134%, respectively. In this combination, a dose reduction of celecoxib can be halved.
Despite the lack of targeted research fluconazole can increase the systemic exposure of other NSAIDs metabolized by the isoenzyme CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). You may need to adjust the dose of NSAIDs.
With the simultaneous use of NSAIDs and fluconazole, patients should be carefully monitored to detect and control adverse events and toxicity associated with NSAIDs.
Oral contraceptives: with simultaneous application of a combined oral contraceptive with fluconazole at a dose of 50 mg, there is no significant effect on the level of hormones, whereas with a daily intake of 200 mg fluconazole AUC ethinyl estradiol and levonorgestrel increased by 40% and 24%, respectively, and when 300 mg of fluconazole is administered once a week AUC Ethinyl estradiol and norethindrone increase by 24% and 13%, respectively. Thus, the repeated use of fluconazole at these doses is unlikely to affect the effectiveness of the combined oral contraceptive.
Phenytoin: simultaneous application of fluconazole and phenytoin may be accompanied by a clinically significant increase in the concentration of phenytoin. If simultaneous use of both drugs is necessary, the concentration of phenytoin should be monitored and its dose adjusted accordingly to ensure therapeutic serum concentration.
Prednisone: there is a report on the development of acute adrenal insufficiency in the patient after liver transplantation with a fluconazole withdrawal after a three-month course of therapy. Presumably, discontinuation of fluconazole therapy caused an increase in the activity of the CYP3 A4 isoenzyme, which led to an increased metabolism of prednisone.Patients receiving combination therapy with prednisone and fluconazole should be carefully monitored when fluconazole is withdrawn to evaluate the condition of the adrenal cortex.
Rifabutin: simultaneous application of fluconazole and rifabutin can lead to an increase in serum concentrations of the latter up to 80%. With the simultaneous use of fluconazole and rifabutin, cases of uveitis are described. Patients simultaneously receiving rifabutin and fluconazole, must be carefully observed.
Saquinavir: AUC increases by approximately 50%, CmOh - by 55%, saquinavir clearance is reduced by approximately 50% due to inhibition of hepatic isoenzyme metabolism CYP3A4 and inhibition of P-glycoprotein. You may need to adjust the dose of saquinavir.
Sirolimus: an increase in the concentration of sirolimus in the blood plasma, presumably due to the inhibition of the metabolism of sirolimus through oppression of the isoenzyme CYP3 A4 and P-glycoprotein. This combination can be applied with appropriate correction of the dose of sirolimus depending on the effect / concentration.
Sulfonylurea preparations: fluconazole, while receiving, increases the half-life of oral sulfonylureas (chlorpropamide, glibenclamide, tolbutamide and glipizide). Patients suffering from diabetes, you can assign the combined use of fluconazole and oral sulfonylureas, but it should take into account the possibility of hypoglycemia also requires regular monitoring of glucose levels in blood and, if necessary, dose adjustment of sulfonylureas.
Tacrolimus: simultaneous application of fluconazole and tacrolimus (inward) leads to an increase in serum concentrations of the latter by a factor of 5 due to inhibition of the metabolism of tacrolimus occurring in the intestine through isoenzyme CYP3 A4. Significant changes in the pharmacokinetics of drugs have not been observed with tacrolimus intravenously. Cases of nephrotoxicity are described. Patients simultaneously taking tacrolimus inside and fluconazole, should be carefully observed. The dose of tacrolimus should be adjusted depending on the degree of increase in its concentration in the blood.
Theophylline: when used simultaneously with fluconazole at a dose of 200 mg for 14 days, the average plasma clearance rate of theophylline is reduced by 18%. In the administration of fluconazole to patients receiving theophylline in high doses, or in patients at increased risk of developing the toxic effect of theophylline, the symptoms of an overdose of theophylline should be monitored and, if necessary, adjusted accordingly.
Vinca alkaloid: Despite the lack of targeted research, it is assumed that fluconazole can increase the concentration of vinca alkaloids (eg, vincristine and vinblastine) in the blood plasma and, thus, lead to neurotoxicity, which may possibly be due to oppression of the isoenzyme CYP3A4.
Vitamin A: there is a report of one case of development of undesirable reactions from the central nervous system (CNS) in the form of a pseudotumor of the brain with simultaneous application of all transretinic acid and fluconazole that disappeared after the withdrawal of fluconazole. The use of this combination is possible, but one should remember about the possibility of undesirable reactions from the CNS.
Zidovudine: when used simultaneously with fluconazole, there is an increase in Stach and AUC zidovudine by 84% and 74%, respectively. This effect is probably due to a decrease in the metabolism of the latter to its main metabolite. Before and after treatment with fluconazole at a dose of 200 mg / day for 15 days with AIDS and ARC (AIDS-related complex), a significant increase AUC zidovudine (20%).
Nevirapine: simultaneous application of fluconazole and nevirapine resulted in an increase in the effect of nevirapine by approximately 100%. In the case of simultaneous use of these drugs, accompanied by a risk of increased exposure to nevirapine, care must be taken and patients carefully monitored. Clinically significant effects of nevirapine on fluconazole was not noted.
Voriconazole (inhibitor of isoenzymes CYP2C9, CYP2C19 and CYP3A4): simultaneous application of voriconazole (400 mg twice a day on the first day, then 200 mg twice a day for 2.5 days) and fluconazole (400 mg on the first day, then 200 mg per day for 4 days) leads to an increase in the concentration and AUC voriconazole by 57% and 79%, respectively. It was shown that this effect persists with a reduction in the dose and / or a decrease in the frequency of administration of any of the drugs.Simultaneous use of voriconazole and fluconazole is not recommended.
Investigations of the interaction of oral forms of fluconazole with its simultaneous administration with food, cimetidine, antacids, and after total body irradiation for the preparation of bone marrow transplantation showed that these factors do not have a clinically significant effect on the absorption of fluconazole.
The above interactions were established with repeated application of fluconazole; interactions with drugs as a result of a single administration of fluconazole are not known. Doctors should take into account that interaction with other drugs has not been specifically studied, but it is possible.